Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination
The review analyzes data on the course and outcomes of axial spondyloarthritis (axSpA) accumulated over the previous 2.5 years of the COVID-19 pandemic. The issues of clinical and immunological efficacy of vaccination against COVID-19 in this disease are considered. It was noted that the presence of...
Saved in:
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA-PRESS LLC
2023-02-01
|
| Series: | Современная ревматология |
| Subjects: | |
| Online Access: | https://mrj.ima-press.net/mrj/article/view/1396 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849399875581509632 |
|---|---|
| author | Sh. F. Erdes B. S. Belov |
| author_facet | Sh. F. Erdes B. S. Belov |
| author_sort | Sh. F. Erdes |
| collection | DOAJ |
| description | The review analyzes data on the course and outcomes of axial spondyloarthritis (axSpA) accumulated over the previous 2.5 years of the COVID-19 pandemic. The issues of clinical and immunological efficacy of vaccination against COVID-19 in this disease are considered. It was noted that the presence of axSpA, as well as treatment with tumor necrosis factor-á inhibitors and non-steroidal anti-inflammatory drugs, did not significantly increase the risk of COVID-19 infection and did not worsen its outcomes, apart from an increase in the incidence of venous thromboembolism. At the same time, it is assumed that anticytokine therapy for SpA may protect against severe COVID-19 course.The data presented suggest that the benefits of vaccination in SpA far outweigh the potential harms associated with the development of adverse events. It has been shown that in patients with SpA, vaccination does not affect the activity of the inflammatory process, and biologic disease modifying antirheumatic drugs have almost no significant effect on the post-vaccination response. |
| format | Article |
| id | doaj-art-cf3098012ec74436be96535c3ccfaaab |
| institution | Kabale University |
| issn | 1996-7012 2310-158X |
| language | Russian |
| publishDate | 2023-02-01 |
| publisher | IMA-PRESS LLC |
| record_format | Article |
| series | Современная ревматология |
| spelling | doaj-art-cf3098012ec74436be96535c3ccfaaab2025-08-20T03:38:13ZrusIMA-PRESS LLCСовременная ревматология1996-70122310-158X2023-02-0117110.14412/1996-7012-2023-1-101-1072558Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccinationSh. F. Erdes0B. S. Belov1V.A. Nasonova Research Institute of RheumatologyV.A. Nasonova Research Institute of RheumatologyThe review analyzes data on the course and outcomes of axial spondyloarthritis (axSpA) accumulated over the previous 2.5 years of the COVID-19 pandemic. The issues of clinical and immunological efficacy of vaccination against COVID-19 in this disease are considered. It was noted that the presence of axSpA, as well as treatment with tumor necrosis factor-á inhibitors and non-steroidal anti-inflammatory drugs, did not significantly increase the risk of COVID-19 infection and did not worsen its outcomes, apart from an increase in the incidence of venous thromboembolism. At the same time, it is assumed that anticytokine therapy for SpA may protect against severe COVID-19 course.The data presented suggest that the benefits of vaccination in SpA far outweigh the potential harms associated with the development of adverse events. It has been shown that in patients with SpA, vaccination does not affect the activity of the inflammatory process, and biologic disease modifying antirheumatic drugs have almost no significant effect on the post-vaccination response.https://mrj.ima-press.net/mrj/article/view/1396axial spondyloarthritisankylosing spondylitiscovid-19vaccinationoutcomes |
| spellingShingle | Sh. F. Erdes B. S. Belov Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination Современная ревматология axial spondyloarthritis ankylosing spondylitis covid-19 vaccination outcomes |
| title | Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination |
| title_full | Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination |
| title_fullStr | Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination |
| title_full_unstemmed | Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination |
| title_short | Axial spondyloarthritis and COVID-19: course, interactions, outcomes, and the role of vaccination |
| title_sort | axial spondyloarthritis and covid 19 course interactions outcomes and the role of vaccination |
| topic | axial spondyloarthritis ankylosing spondylitis covid-19 vaccination outcomes |
| url | https://mrj.ima-press.net/mrj/article/view/1396 |
| work_keys_str_mv | AT shferdes axialspondyloarthritisandcovid19courseinteractionsoutcomesandtheroleofvaccination AT bsbelov axialspondyloarthritisandcovid19courseinteractionsoutcomesandtheroleofvaccination |